Ribavirin is under clinical development by Bausch Health Companies and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ribavirin’s likelihood of approval (LoA) and phase transition for Hemorrhagic Fever took place on 09 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ribavirin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ribavirin overview

Ribavirin (Virazole, Virazide, Viramid, vilona) is a synthetic nucleoside with antiviral activity. It is formulated as capsule for oral route of administration and powder for solution for inhalational route of administration. Ribavirin is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV). Ribavirin is indicated for emergency use in the treatment of COVID-19. Ribavirin is also indicated for several viral infections like herpes labialis, herpetic gingivostomatitis, primary and recurrent genital herpes including prophylaxis; herpes zoster and chickenpox in immunocompetent and immunosuppressed patients, mumps, acute viral hepatitis A, B and C, and chronic B and C, parainfluenza and influenza A and B.

It is under development for the treatment of hemorrhagic fever with renal syndrome as intravenous formulation and for the treatment of adult patients with respiratory distress due to COVID-19.

Bausch Health Companies overview

Bausch Health Companies (Bausch Health), formerly Valeant Pharmaceuticals International Inc, is engaged in the manufacturing, development, and marketing of a range of medical devices, over-the-counter products (OTC), and pharmaceutical products. Bausch Health offers products for therapy areas related to dermatology, gastroenterology, eye health, neurology, aesthetic devices, dentistry, and consumer health. It offers various generic and branded generic products. Bausch Health has administrative, research and laboratory, marketing, distribution, and warehousing facilities worldwide. The company offers products directly or indirectly in various regions across the world including the US, Canada, Africa, Middle East, Australia, Latin America, and Europe. It also operates manufacturing facilities in the US, Brazil, Columbia, Germany, Canada, among others. Bausch Health is headquartered in Laval, Quebec, Canada.

Quick View Ribavirin LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Ribavirin
Administration Pathway
  • Inhalational
  • Intravenous
  • Oral
Therapeutic Areas
  • Infectious Disease
  • Respiratory
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.